Cyclo Therapeutics, Inc. (CYTH) Misses Q2 EPS by 7c

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) reported Q2 EPS of ($0.41), $0.07 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $542 thousand versus the consensus estimate of $571 thousand.

For earnings history and earnings-related data on Cyclo Therapeutics, Inc. (CYTH) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• XP Inc eyes US banking license as next business step
• CalPrivate Bank names Andra Frazier as chief credit officer